Healthcare Guidance
Guidance, reporting, patient handouts and more from MSDH
MS-HAN Messages
Advisories and information related to COVID-19 from the Mississippi Health Alert Network
Therapeutics
- Paxlovid ordering, reporting and resources
- COVID-19 Therapeutics Decision Aid
- Outpatient Administration Guide for Healthcare Providers (HHS.gov) Federal Response to COVID-19: Therapeutics Clinical Implementation Guide
- All therapeutics resources
Healthcare Provider Guidance and Resources
- CDC Infection Control Recommendations for Healthcare Professionals During COVID-19
- NIH Clinical Guidelines: Therapies for High-Risk, Nonhospitalized Patients
- NIH Panel's Statement on Prioritizing the Use of Outpatient Therapies
- CDC Guidance for Healthcare Personnel with Potential COVID-19 Exposure
- Handout: What to Do After You Have Been Tested for COVID-19
- Handout: Home Isolation for Individuals with COVID-19
- CDC guidance related to COVID-19
Patient Handouts
Vaccination Providers
Reporting COVID-19 Cases
- Updated SARS-CoV-2 Reporting RequirementsMarch 31, 2022
- Electronic Reporting of COVID-19 Test Results to MSDHOptions and data formats
- Request NBS Account for COVID-19 ReportingChoose this option if you run non-rapid, non-point-of-care COVID-19 tests (typically hospitals, reference labs, large clinic systems, etc.)
- Sign up for Simple Report for COVID-19 ReportingThis reporting tool only works with rapid and point-of-care COVID-19 tests (typically clinics, schools, and non-traditional testing sites). These facilities can view and edit data entered.
COVID-19 Therapeutics
- Therapeutics locator
- Billing for COVID-19 therapeutics
- Monoclonal antibody therapy
- Evusheld
- Oral antivirals
- Remdesivir
- Contact information for Mississippi COVID-19 therapeutics providers PDF
- Overview of Therapeutics for the Prevention or Treatment of COVID-19 (HHS.gov) PDF
Monoclonal Antibody Therapy
There are no monoclonal antibodies currently authorized in the U.S. for the outpatient treatment of COVID-19.
The following monoclonal antibody products are no longer authorized for use in the U.S.:
- Bamlanivimab
- Bamlanivimab/Etesevimab
- Bebtelovimab
- REGEN-COV
- Sotrovimab
Evusheld
As of January 26, 2023, Evusheld is no longer authorized for Emergency use for pre-exposure prophylaxis (prevention) of COVID-19.
Oral Antivirals
Ordering: The federal government has designed the Healthcare Provider Order Portal (HPOP) for management of COVID-19 therapeutics. Please place your order in HPOP. You will be able to see courses ordered for your site on your HPOP account. If you do not have an HPOP account, please contact C19Therapeutics@msdh.ms.gov
Required reporting: Courses administered and courses available of Paxlovid and molnupiravir should be entered into HPOP by the provider site at the end of every business day. Timely and accurate inventory reporting is necessary for federal partners to determine subsequent state allocations
Resources:
- PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers (FDA)
- Paxlovid Resources from Pfizer.com
- Paxlovid fact sheet for healthcare providers (FDA)
- Paxlovid fact sheet for patients/caregivers (FDA)
- Molnupiravir resources from Merck.com
- Molnupiravir fact sheet for healthcare providers (FDA)
- Molnupiravir fact sheet for patients/caregivers (FDA)
Find pharmacies that prescribe and dispense oral antivirals
Therapeutics Locator
Use this interactive map to locate a facility that has one of the authorized therapeutics for COVID-19.
Presentation: Oral Antiviral Therapeutics
Overview and details of use, safety, interactions, target population and more (July 19, 2022)
Remdesivir
Remdesivir has been studied in non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease and is approved by the FDA for use in both hospitalized and non-hospitalized patients.
Ordering: Remdesivir is commercially available and should be ordered through standard pharmaceutical procurement processes.
Billing for COVID-19 Therapeutics
Health Facilities
Specimen Collection, Delivery and Reporting
- COVID-19 Specimen Collection
- COVID-19 Lab Requisition Form
- COVID-19 Refrigerated Specimen Packaging
- COVID-19 Frozen Specimen Packaging
- COVID-19 Specimen Transport and Delivery
Specimen Reporting
SARS-CoV-2 Virus Strain Surveillance
- COVID-19 Enhanced Surveillance Submission Recommendations
- SARS-CoV-2 Enhanced Surveillance Submission Requisition Form 1198
Map and Directions for Laboratory Dropoff
The Dr. F.E.”ED” Thompson, Jr. Public Health Laboratory Facility is on the State Department of Health's central office campus in Jackson, MS at 350 East Woodrow Wilson Drive, Jackson, 39216.
Local Delivery of Samples: Drop samples off at the rear of the Thompson lab building. Detailed instructions are in our sample shipping guidance.
Dropoff hours: Monday through Friday from 8:00–4:30.
CDC Guidance
Healthcare and EMS
- Home Care Guidance
- Discontinuation of Home Isolation for Persons with COVID-19
- Healthcare Infection Control Guidance
- Clinical Care Guidance
- Healthcare Personnel with Potential COVID-19 Exposure Guidance
- Inpatient Obstetric Healthcare Guidance
- Guidance for EMS
Contact Tracing
- Contact Tracing Information and Guidance
- Collection and Submission of Postmortem Specimens from Deceased Persons with Confirmed or Suspected COVID-19
